Our Mission

To transform the lives of patients living with autoimmune diseases.

Our Pipeline

Rapidly advancing a deep portfolio of innovative autoimmune therapeutics that continues to expand through our successful business development strategy.

Latest News

January 11, 2023

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

November 7, 2022

Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

long-arrow-right-regularfacebook-brandsfacebook-f-brandsinstagram-brandslinkedin-brandslinkedin-in-brandssubmit-arrowtwitter-brandstwitter-square-brandsyoutube-brands